{"name":"Eisai Korea Inc.","slug":"eisai-korea-inc","ticker":"","exchange":"","domain":"","description":"Eisai Korea Inc. is a subsidiary of Eisai Co., Ltd., focusing on the development and commercialization of innovative pharmaceutical products in South Korea. The company has a diverse portfolio including marketed drugs such as Safinamide Mesilate and Pariet, with ongoing research in various therapeutic areas.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"zonisamide high dose group","genericName":"zonisamide high dose group","slug":"zonisamide-high-dose-group","indication":"Epilepsy (adjunctive therapy for partial seizures)","status":"marketed"},{"name":"Aricept","genericName":"Aricept","slug":"aricept","indication":"Alzheimer's disease","status":"marketed"},{"name":"zonisamide low dose group","genericName":"zonisamide low dose group","slug":"zonisamide-low-dose-group","indication":"Epilepsy (adjunctive or monotherapy for partial seizures)","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Pariet","genericName":"Pariet","slug":"pariet","indication":"Other","status":"marketed"},{"name":"Safinamide Mesilate","genericName":"Safinamide Mesilate","slug":"safinamide-mesilate","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"zonisamide high dose group","genericName":"zonisamide high dose group","slug":"zonisamide-high-dose-group","phase":"marketed","mechanism":"Zonisamide is a sulfonamide anticonvulsant that reduces neuronal excitability by blocking sodium and calcium channels and enhancing GABAergic inhibition.","indications":["Epilepsy (adjunctive therapy for partial seizures)","Generalized tonic-clonic seizures"],"catalyst":""},{"name":"Aricept","genericName":"Aricept","slug":"aricept","phase":"marketed","mechanism":"Beta-secretase 1, Multidrug resistance protein 1, Acetylcholine receptor subunit epsilon","indications":["Alzheimer's disease","Moderate to Severe Alzheimer's Type Dementia"],"catalyst":""},{"name":"Pariet","genericName":"Pariet","slug":"pariet","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Safinamide Mesilate","genericName":"Safinamide Mesilate","slug":"safinamide-mesilate","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"zonisamide low dose group","genericName":"zonisamide low dose group","slug":"zonisamide-low-dose-group","phase":"marketed","mechanism":"Zonisamide inhibits multiple ion channels and carbonic anhydrase to reduce neuronal excitability and seizure activity.","indications":["Epilepsy (adjunctive or monotherapy for partial seizures)","Generalized tonic-clonic seizures"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxNSXBvSjJ0ckFhWDFIZ2k2dENaVkowZGQ3enVNNHpITHNoamVKREEzSXgzSmRJSUEzOXA1S01sSmttMHlUUjNCczJ4TklrSHVoYmlwMm92QnRtT2drNHVBVEM2Z0pxbExKdFdJSnkwSV9IM1RmNm1KcU1sQkVveERDcUpsdTdiTFNGbWJub0FaQ2NiU1ZaNnNQR0ZXZzhNQUYzbjFuZFBLNG5vSko4eUd1TTNfSkxnQWkyZ1hIU2dnMDllQlZWalNMWHNvZ2RHOG9vSFhST09Wc3gwSEkyZjdROVRBcS1GTUk0VHp6U1U2Vlo5YU5qc2xNT0F2LS1HVC1pVTR3NFZsNE13eVJUUThVRGtjMXVTOWs?oc=5","date":"2026-01-07","type":"trial","source":"BioSpace","summary":"EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan - BioSpace","headline":"EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treat","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOeEp5N3NyWWR6NnNieWJ2Y1NpRjRIeGlyZVVjSmVqNXRxNVpVQnFIclhFZEpFRURncmVyUDltRFlnWFJzME9fYThfQjNKRWd2ZVNIWExOOWEtTWVTOVdSVExHY2hNdG02dXVrMmFLRVhWVjNyU3dCMEhzcEV2MzREeUpOYjJ5dlJJYnl2akg1TWo5VGtPRW1xTVo1aw?oc=5","date":"2025-08-19","type":"pipeline","source":"BioWorld News","summary":"Microsphere injectables biotech G2Gbio debuts with $38M - BioWorld News","headline":"Microsphere injectables biotech G2Gbio debuts with $38M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxORV9rNzJNLWJ2WWxXTktiM05GaUE3a3k2Z3dub2hlREZWUGdvVDBNT05Xbmh2U1lUWmFfMzFHaHhJY1Rhb2FmNWx6M3hwNW54YXQxeEZ3UFE1U1AyNy1JUVM4TTVLYVdEdGpkenJpaUZ1a2tyLUh6LWhMRGJjZVF5LUtVWmRPVTBVaXNKNXpTU2dNck5OaE1raVRYd1dwUXh4alRsemtURkZJc0VlUE1SdmpSYVpsZE16eXFuV3llaURzSVJ3MUtRYy1yYWFEaFJKZG42YndSbmhOV0U?oc=5","date":"2025-04-22","type":"pipeline","source":"PR Newswire","summary":"XADAGO/EQUFINA Set to Revolutionize Parkinson's Disease Treatment Landscape | DelveInsight - PR Newswire","headline":"XADAGO/EQUFINA Set to Revolutionize Parkinson's Disease Treatment Landscape | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQOTlfUUxiSVY1SHNFWVhjcHFNWVU3dUR0Rk1OX21pa0x6aEpZSXphM0ZVSUhIRE5mMUpzWEtsN2c3R3BLVUc1TkNFTmxzUzJCSGcxWkRvWl85Vk9CZXhtc3ROWXExVzBTU1ozN29tWW13RnhvRXNabFhiUkpNMHVFSXB5VHloOXVnaFRsZGxrSHFTaGtrSmhEZTlTajlfOElLWC1nWVhUckprdkJpc0lNUlphbUg4aDFlNEVOV0ZjNXVBcjg?oc=5","date":"2025-04-14","type":"regulatory","source":"Biogen","summary":"Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease by the European Commission - Biogen","headline":"Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease by the European Commission","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwJBVV95cUxPYjdiX0tmNzBiWVNxY2V4ZHByVGZHQzlScUt6dGREN08yUVItS3c1aWpQYjMtZE9INWwyT3BCR2dsMUtONEFOeWVXYS16bmJySVhfSHhuazlXaU8xMjFHcHVTZS1FNHdXbGZSeEN5TkxjS3JaRGtKZ0NYV2xSWk9sMTFoRHh2TDB0ZE85RWFLcjJZUTItVzkyWGlvbkd1M3hyNzFucmRtTU41LVZOQ1pfMlQ5dHhxTXpHRU9pa0h5ckhCVlJIUmRvUHZVdi1uaWdHSEExQWcwYjkzQWtOa2JSR1JMVnZvZkhNUW1Tai0xRnZfZXVkN194Tk5uVFItWm9xeFdSSFZDM0ltcm9jemxWeHFHb01tb0YyTFUyTV9aTWxDeWVOekpld3Vpaw?oc=5","date":"2025-03-25","type":"regulatory","source":"PR Newswire","summary":"EISAI TO PRESENT LECANEMAB REAL-WORLD EXPERIENCE DATA AND FINDINGS FROM NEUROLOGY PORTFOLIO AT THE AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING - PR Newswire","headline":"EISAI TO PRESENT LECANEMAB REAL-WORLD EXPERIENCE DATA AND FINDINGS FROM NEUROLOGY PORTFOLIO AT THE AMERICAN ACADEMY OF N","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOMXRMNk1OdFU2RnQ3NHd2bVF6OWRlZTk5MTAza0YzNGpsT0phbngyYnFScU1WYWdzN0JsdzBOV2ZrUnNrY0tMOFNnUG1oamJmcm9kcGVOOWlxTEhtNW1rb29ySUswTklvdXJSQUVCMXNkUFlfRVc1QTRRd3p0ZFFtVjFBcHRJdVRLZ29FZUtvelNwTXg5M1RQWVdrQVVtRWNJcVBSajFhZXdUeUltbnROS2E0dGxLdHdvRjM5NUZjOUlPUQ?oc=5","date":"2025-03-03","type":"regulatory","source":"Biogen","summary":"Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer’s Disease in Australia - Biogen","headline":"Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer’s Disease in Australia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPbUxuWTFndzA5Zkg5UkdPVEFPOFBWS19DM29ENzVoRHNDSTZ3RGhfTlRrU18wQmtGMUo2YlZ1eHpWelVMZnhWQ1o1V01aOXJhOWdRcUZiYm9MNjVlTDFoeUprd0lTOXkyVFRTQ1MtVE5rWUdVU2dqajNGNHFNZXR1OFFHQjQ1UUNuLVBLalFFbnlUcWVwb0V5VE41dWJZcFdiSHk4UkFmRUd3N3pOcDdCSF9IOHRlZ3dmWXlUVA?oc=5","date":"2025-02-28","type":"pipeline","source":"Stock Titan","summary":"Biogen's Alzheimer's Drug Clears Critical EU Hurdle After Safety Review - What This Means for 22M Potential Patients - Stock Titan","headline":"Biogen's Alzheimer's Drug Clears Critical EU Hurdle After Safety Review - What This Means for 22M Potential Patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE1QMmNxV0hJWXJydklzVjdKN2JHcXdFOHdxS18xY2pDLW1NbHFmajhpWHJpbzBDdUZrMFBERVVOWEtrWFh5Z2NPREJITTBFXzVEUnE3Tkg2RVBkcnN4enJuSGFTSmZKa1dGaElQR1hn0gFyQVVfeXFMTlJJOTBmbkttS2VoMEFZUUhLNDZtOVRzVjFpMnVLcUw1ekRuQ1BMbFpONFV1blVxMU9QVDhEQmtRTW4xTE9MRUhEeXBNcnVWOVZLR2ZJS3dPWW40OW03ZzNvUWVkMzVRNnNsVi1FRW8tVll3?oc=5","date":"2024-11-28","type":"pipeline","source":"koreabiomed.com","summary":"Eisai launches Alzheimer’s treatment Leqembi in Korea - koreabiomed.com","headline":"Eisai launches Alzheimer’s treatment Leqembi in Korea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxPZHZqUmdiaGd6SUVaeC1KSWtfQlRfVGJYMGRENkFuOFNnMkZrN2JMYmpsYlRzS3NyNE1HRS04anFMY1Q1a3ZnMndjLTZ5WU5IRDFySmJKWUFVRVJBek9QaHBOTkk0ZUpSQWVpVHRCR3k5SlBKbUg1clRGN3I2dHBTRC13a2FBWi1VTmctaDFKOVlYS2Q4bVlfV2ZwUnJ5Z1VhWVRyeHh2V29vUXFwcndianRMYVpHVkhsRGNQNTRiaG04T0dTTWFwTEo3ejBwanN2OUc0?oc=5","date":"2024-11-27","type":"regulatory","source":"PR Newswire","summary":"\"LEQEMBI®\" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea - PR Newswire","headline":"\"LEQEMBI®\" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxOZUdXZ21JRmlzTEwwRGJ5cnhUdjJLc0JQSkRUQ0RYV281bXIwSkdkT3h0VkdaMmp3Q0liX0UyMTdPMGZXck9TSHBMcFRseUtoU3gyS0ZkRHVacTM0eHB1XzRVaGh6NmtWQldjZWNwcndZREpqYWtGSURacjFFSm5FR0l4RE5XTUNWbllvMTBYTmJqQTRBWXVkRE1zNTRkZmJ4cWp6cWoteG15bWRFcWIzejJwSFFqYm5aVlRUaTZucnBjWHlmejE4bzNiTXBRTms?oc=5","date":"2024-05-28","type":"regulatory","source":"BioSpectrum Asia","summary":"Eisai's LEQEMBI receives approval in South Korea for treatment of Alzheimer's Disease - BioSpectrum Asia","headline":"Eisai's LEQEMBI receives approval in South Korea for treatment of Alzheimer's Disease","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTFAyM1R2ZENMTVJoUzcwRmhsWmdickMyZDhxUlNKVG9rcExwTlJaeHJ2b0pQSHVBNHpBMWFFVVlJYmZiblNIaTlSR0ZUZ2tjb1llSU5TT1lJZE1Odw?oc=5","date":"2021-02-19","type":"pipeline","source":"Eisai","summary":"Video Library | About Eisai - Eisai","headline":"Video Library | About Eisai","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVkFVX3lxTE9lVThmTkxjRWlWYlBKLW1xUF9udWdFT1hJMUZVNkxIbmRkQkJpeV9ZbXFwU0JkZjdSUlJfS050NkYwdjhPMDJzTFRaZnFvaDFucEtMXzF3?oc=5","date":"2018-06-18","type":"pipeline","source":"Eisai","summary":"activity “NOW Project” aiming to contribute to the creation of a society that coexists with patients and people with disabilities - Eisai","headline":"activity “NOW Project” aiming to contribute to the creation of a society that coexists with patients and people with dis","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"marketed":5},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}